Close this search box.

Sensus Healthcare Launches Collaboration with BirchBioMed to Treat and Prevent Scarring for Keloids Patients Around the World

February 5, 2018

BOCA RATON, Fla., Feb. 5, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today Sensus’ collaboration with BirchBioMed Inc., a biomedical company focused on anti-scarring drugs, to treat and prevent scarring more effectively for patients who are afflicted with keloids.

“This partnership unites our joint efforts to eliminate the suffering of millions of people who have disfiguring keloids and other scars,” said Mark Miller, Chairman and CEO of BirchBioMed. “Combining Sensus’ innovative use of SRT with BirchBioMed’s late-stage FS2 product candidates takes the treatment of keloids scars to the next level. This is especially revolutionary given that expensive cosmetic treatments on the market show little, if any, efficacy in treating scars. Medical alternatives are also costly, painful for the patient and focused on healing wounds, not on preventing and eliminating scars altogether.”

Sensus’ SRT delivers precise, calibrated low-dose radiation that effectively destroys the non-malignant tumor cells that cause keloids and other scars. BirchBioMed’s pipeline of fibrosis-targeted treatments, including FS2, prevents the formation of external and internal scars on the molecular level by targeting excessive scar protein formation that results from repair of an injury, surgery and as a consequence of chronic disease. To date, there has been no therapeutic agent approved by the FDA that targets scarring on the molecular level.

“BirchBioMed has the means to provide cost-effective products that will work in conjunction with Sensus’ SRT to prevent and / or eliminate scarring,” added Joe Sardano, President and CEO of Sensus Healthcare. “This is all about creating better products at a lower cost for patients with scars, and especially keloids, and this collaboration will ultimately create more effective options for both doctors and patients moving forward.”

About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit

About BirchBioMed
BirchBioMed Inc. is a biomedical company focused on the commercialization, clinical evaluation and development of proprietary anti-scarring drugs, autoimmune therapeutics/therapies and novel strategies for transplantation. As a University of British Columbia (UBC) spinoff, BirchBioMed holds the exclusive, worldwide pharmaceutical license for two medical therapeutic technologies from UBC, which the university considers to be significant medical breakthroughs in the treatment of scarring and certain autoimmune diseases.

Media Contacts:
Caitlin Kasunich / Kathryne Hunter
KCSA Strategic Communications
212-896-1241 / 212-896-1204
[email protected] / [email protected]

Cision View original content:

SOURCE Sensus Healthcare